Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.64 |
| ▸ | MAOA | P21397 | 7/20 | 0.64 |
| ▸ | GRM5 | P41594 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | TOP1 | P11387 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10088411 | 0.88 | MAOB (0.65) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL281588 | 0.78 | MAOB (1.00) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL450942 | 0.78 | MAOB (0.56) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL2325236 | 0.77 | MAOB (0.65) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL10088462 | 0.76 | S1PR1 (0.50) | MAOBMAOANPC1ALDH1A1RAB9A | |
| SCHEMBL10088922 | 0.76 | SRD5A1 (0.47) | MAOBMAOA | |
| SCHEMBL29771008 | 0.75 | MAOB (0.37) | MAOBMAOAGRM5NPC1RAB9A | |
| SCHEMBL13235118 | 0.74 | MAOB (0.58) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL12214576 | 0.74 | MAOB (0.58) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL2327566 | 0.74 | MIF (0.47) | MAOBMAOAALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2354134-B1 | 2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR | ASTELLAS PHARMA INC (JP) | 2016-02-24 | — | — | EP | disclosed |
| EP-2354134-B1 | 2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR | ASTELLAS PHARMA INC (JP) | 2016-02-24 | — | — | EP | disclosed |
| CN-102239164-B | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC | 2013-10-30 | — | — | CN | disclosed |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| CN-102239164-A | 2h-chromene compound and derivative thereof | ASTELLAS PHARMA INC | 2011-11-09 | — | — | CN | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2354134-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | Astellas Pharma Inc. (JP) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010064707-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | アステラス製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | MAOB 2521/4885MAOA 2123/4885GRM5 1852/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | MAOB 3106/4885MAOA 2984/4885GRM5 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.